Clinical Report: Neonatal Health Outcomes Associated with Prenatal Use of SSRIs

Overview

This study evaluates neonatal outcomes associated with prenatal exposure to selective serotonin reuptake inhibitors (SSRIs) using a target trial emulation framework. Findings indicate that SSRI continuation during pregnancy may be associated with lower Apgar scores and higher odds of meconium in amniotic fluid, while congenital anomalies did not differ significantly between groups.

Background

Depression affects approximately 26% of women over their lifetime, and SSRIs are commonly prescribed during pregnancy. The ability of SSRIs to cross the placenta raises concerns about potential adverse neonatal health outcomes. Understanding these risks is crucial for informed clinical decision-making regarding the management of maternal depression during pregnancy.

Data Highlights

Key Findings

• SSRI continuation during pregnancy is associated with lower Apgar scores at 1 and 5 minutes.
• Higher odds of meconium in amniotic fluid were observed in the SSRI continuation group.
• No significant differences in NICU admission rates were noted between SSRI-exposed and non-exposed groups.
• Congenital anomalies did not differ significantly between SSRI-exposed and non-exposed pregnancies.
• The study utilized a target trial emulation framework to address biases in traditional observational studies.

Clinical Implications

Clinicians should consider the potential neonatal outcomes associated with SSRI use during pregnancy, particularly regarding Apgar scores and meconium presence.

Conclusion

The findings from this study contribute to understanding the implications of SSRI use during pregnancy.

Related Resources & Content

1. ACOG, ACOG, 2025 -- Statement on the Benefit of Access to SSRIs During Pregnancy
2. Neonatal Outcomes Following Selective Serotonin Reuptake Inhibitor Use During Pregnancy, JAMA Network, 2023 -- Neonatal Outcomes Following Selective Serotonin Reuptake Inhibitor Use During Pregnancy
3. Drug Safety — Are Antidepressants Best Avoided During Pregnancy?
4. Drugs - Real World Outcomes — Antidepressant Administration in Pregnant Women and Its Possible Impact on Motor Skills and Cognitive Development in Children: A Comprehensive Review
5. BMJ Mental Health — Congenital malformation risk following prenatal antipsychotic exposure: a systematic safety surveillance approach
6. Drugs - Real World Outcomes — Investigating the Impact of Duloxetine Use in Pregnancy on the Likelihood of Small for Gestational Age or Preterm Birth: A Comprehensive Study from Denmark and Sweden
7. ACOG Statement on the Benefit of Access to SSRIs During Pregnancy | ACOG
8. Neonatal Outcomes Following Selective Serotonin Reuptake Inhibitor Use During Pregnancy | Clinical Pharmacy and Pharmacology | JAMA Network Open | JAMA Network
9. https://cdn-links.lww.com/permalink/aog/d/aog_141_6_2023_05_04_cpg_23-580_sdc4.pdf